Azepanone-based inhibitors of human and rat cathepsin K

Journal of Medicinal Chemistry

Volumn 44, Issue 9, 2001, Pages 1380-1395

  Marquis, R W ^a   Ru, Y ^a   LoCastro, S M ^a   Zeng, J ^a   Yamashita, D S ^a   Oh, H J ^a   Erhard, K F ^a   Davis, L D ^a   Tomaszek, T A ^a   Tew, D ^a   Salyers, K ^a   Proksch, J ^a   Ward, K ^a   Smith, B ^a   Levy, M ^a   Cummings, M D ^b   Curtis Haltiwanger, R ^a   Trescher, G ^a   Wang, B ^a   Hemling, M E ^a   Quinn, C J ^a   Cheng, H Y ^a   Lin, F ^a   Smith, W W ^a   Janson, C A ^a   Zhao, B ^a   McQueney, M S ^a   D'Alessio, K ^a   Lee, C P ^a   Marzulli, A ^a   Dodds, R A ^c   Blake, S ^a   Hwang, S M ^a   James, I E ^a   Gress, C J ^a   Bradley, B R ^a   Lark, M W ^a   Gowen, M ^a   Veber, D F ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b JOHNSON AND JOHNSON   (United States)

^c OSIRIS THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZEPANONE; CATHEPSIN K; CYSTEINE PROTEINASE; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOAVAILABILITY; BONE TURNOVER; CELL STRAIN CACO 2; CHIRALITY; CONFORMATIONAL TRANSITION; ENZYME INHIBITION; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOLECULAR MODEL; NONHUMAN; RAT; STEREOCHEMISTRY; SYNTHESIS; X RAY CRYSTALLOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; BIOLOGICAL AVAILABILITY; CATHEPSINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HUMANS; LEUCINE; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OSTEOCLASTS; PROTEIN BINDING; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035953314     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000481x     Document Type: Article

References (69)

1. Cathepsin K, but not cathepsins B, L or S is abundantly expressed in human osteoclasts
2. Human cathepsin 02, a novel cysteine protease highly expressed in osteoclastomas and ovary. Molecular cloning, sequencing and tissue distribution
3. Molecular cloning of human cathepsin O, a novel endoproteinase homologue of rabbit OC2
4. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry
5. Proteolytic activity of human osteoclast cathepsin K. Expression, activation, and substrate identification
6. Cathepsin K antisense oligodeoxy-nucleotide inhibits osteoclastic bone resorption
7. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice
8. Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization
9. Cathepsin K; isolation and characterization of the murine cDNA genomic sequence, the homologue of the human pycnodysostosis gene
10. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis
11. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency
12. Inhibition of cysteine proteases
13. The therapeutic potential of advances in cysteine protease inhibitor design
14. Cathepsin K and the design of inhibitors of cathepsin K
15. Protease inhibitors: Current status and future prospects
16. Cysteine proteases and their inhibitors
17. Structure and design of potent and selective cathepsin K inhibitors
18. Use of X-ray co-rystal structures and molecular modeling to design potent selective non-peptide inhibitors of cathepsin K
19. Use of papain as a model for the structure-based design of cathepsin K inhibitors: Crystal structures of two papain-inhibitor complexes demonstrate binding to S′-subsites
20. Novel inhibitors of the osteoclast specific cysteine protease, cathepsin K
21. Conformationally constrained 1,3-diaminoketones: A series of potent selective inhibitors of the cysteine protease cathepsin K
22. Cyclic ketone inhibitors of the cysteine protease cathepsin K
23. Orally bioavailable inhibitors of the cysteine protease cathepsin K
24. Nitrile oxides in medicinal chemistry-2. Synthesis of the two diastereomers of dihydromuscimol
25. Ring-opening metathesis polymerization (ROMP) of polystyrene by group VIII carbene complex in protic media
26. The application of catalytic ring-closing olefin metathesis to the synthesis of unsaturated oxygen heterocycles
27. Catalytic ring-closing metathesis of dienes: Application to the synthesis of eight-membered rings
28. Synthesis of conformationally restricted amino acids and peptides employing olefin metathesis
29. Recent advances in olefin metathesis and its application in organic synthesis
30. Total synthesis of balanol, part 1. Enantioselective synthesis of the hexahy-droazepine ring via chiral epoxidesaziridines
31. Total synthesis of balanol 2. Completion of the synthesis and investigation of the structure and reactivity of two key heterocyclic intermediates
32. Propane-1,3-dithiol: A selective reagent for the efficient reduction of alkylaryl azides to amines
33. Sulfur trioxide in the oxidation of alcohols by dimethyl sulfoxide
34. Solid-phase synthesis of a combinatorial array of 1,3-bis(acylamino)-2-butanones, inhibitors of the cysteine proteases cathepsins K and L
35. Synthesis of an analogue of tabtoxinine as a potential inhibitor of D-alanine: D-ligase (ADP forming)
36. Stereocontrolled synthesis of erythro N-protected α-amino epoxides peptidyl epoxides
37. Conformationally restricted amino acids and dipeptides, (non)peptidomimetics secondary structure mimetics
38. Peptide conformation and biological activity
39. Development and characterization of a human in vitro resorption assay: Demonstration of utility using novel antiresorptive agents
40. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption
41. Cynomolgus monkey (Macaca fascicularis) cathepsin K: Cloning, expression, purification activation
42. The nature of π-π interactions
43. De novo design, synthesis and X-ray crystal structures of the pyrrolidinone-based β-strand peptidomimetics
44. J. Med. Chem.
45. Experimental and computational approaches to estimate solubility and permeability in drug discovery
46. Design principles for orally bioavailable drugs
47. Physiochemical drug-delivery considerations for oral bioavailability
48. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
49. Role of P-glycoprotein and cytochrome P-450 3A in limiting oral absorption of peptidespeptidomimetics
50. Methods for evaluating intestinal permeability and metabolism in vitro
51. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology
52. Peptide backbone modifications: Structure-activity analysis of peptides containing amide bond surrogates, conformational constraints and related backbone replacements
53. The influence of peptide structure on transport across caco-2 cells. II. Peptide bond modification which results in improved permeability
54. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
55. P-glycoprotein and multidrug resistance
56. Biochemistry of multidrug resistance mediated by the multidrug transporter
57. Crystal structure of human osteoclast cathepsin K complex with E-64
58. Macromodel - An intergrated software system for modeling organic and bioorganic molecules using molecular mechanics
59. Merck molecular force field. I. Basis, form, scope, parametrization, and performance of MMFF94
60. MMFF VI. MMFF94's option for energy minimization studies
61. Semianalytical treatment of solvation for molecular mechanics and dynamics